Promoter holding
64.27%
BD
Beta Drugs Limited - Due diligence report
A 360° intelligence report on Beta Drugs: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Beta Drugs — 360° Intelligence Report
Generated from MCA filings & public records82/100
Trust Score
Low Risk
Beta Drugs is assessed as Low Risk with a Trust Score of 82/100. Beta Drugs is an active public limited indian non-government company incorporated in 2005, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Beta Drugs Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
35/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
- Externally credit-rated (BBB-).
Charges position: 18 open (46.61 cr) · 29 satisfied (23.14 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 7 | 48.0 cr |
| Sidbi | 8 | 48.0 cr |
| Others | 15 | 48.0 cr |
| Uco Bank | 2 | 48.0 cr |
| Axis Bank Limited | 4 | 48.0 cr |
| Vijaya Bank | 11 | 48.0 cr |
Compliance Score: 85/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- Delayed payments to MSME suppliers disclosed (99 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 35/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ROHIT PARTI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAHUL BATRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AJAY MAHIPAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY SEHGAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VARUN BATRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIPUN ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIPUN ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANMOHAN KHANNA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHUTOSH SHUKLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BALWANT SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rajni Charaya | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MONICA JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Lalit Kumar Watts | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rajni Brar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 14 directors on the board.
- MONICA JAIN has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
3
Capital events
3 allotment(s) · 4 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Adley Formulations Private Limited | Subsidiary Company | 74.00% |
| Adley Lab Limited | Subsidiary Company | 74.00% |
| Beta Reseach Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: RAHUL BATRA (Managing Director) · VARUN BATRA (Managing Director) · NIPUN ARORA (CFO) · NIPUN ARORA (CFO) · ASHUTOSH SHUKLA (Whole-time director) · BALWANT SINGH (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
EPFO headcount growing - hiring signal.
Operating for 20+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 director exits within 2 years.
18 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.87 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment92/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 18 open charge(s) of 46.61 cr already registered.
- Compliance record supports lending.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events03 Dec 2025
Charge satisfied
Hdfc Bank Limited
30 Sep 2025
Last AGM held
Annual general meeting
08 Sep 2025
Charge created
Sidbi - 1.42 cr
02 Jul 2025
Charge created
Sidbi - 1.50 cr
15 May 2025
Charge created
Others - 7.00 cr
24 Apr 2025
Charge satisfied
Others
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Mar 2025
Charge created
Axis Bank Limited - 1.98 cr
27 Mar 2025
Charge created
Sidbi - 3.00 cr
10 Mar 2025
Director ceased
MONICA JAIN
Director ceased
Lalit Kumar Watts
05 Feb 2025
Director appointed
MONICA JAIN (Director)
Director appointed
Lalit Kumar Watts (Director)
20 Dec 2024
Director ceased
AJAY MAHIPAL
Director ceased
SANJAY SEHGAL
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
14 active director(s) / partner(s); review board churn before relying on management continuity.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of BBB- from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
2 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Chemcon | L24231GJ1988PLC011652 | Baroda, Gujarat, India |
| Nestorpharma | U24231DL1975PLC007959 | New Delhi, Delhi, India |
| Paushak | L51909GJ1972PLC044638 | Vadodara, Gujarat, India |
| Ambey Iron Private Limited | U13100GA2003PTC003274 | Panaji, Goa, India |
| Viyash | U24239TG2019PTC130774 | Hyderabad, Telangana, India |
| Sequent | L99999TS1985PLC196357 | Shaikpet, Telangana, India |
| Sanginita Chemicals | L24100GJ2005PLC047292 | Gujarat, Gujarat, India |
| Agastya Agro | U01122TG1995PLC019729 | Andhra Pradesh, Telangana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Beta Drugs before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Beta Drugs: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Beta Drugs - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Beta Drugs pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Beta Drugs - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Beta Drugs an active company?
Beta Drugs has MCA status “Active” with a compliance score of 85/100 (Low Risk).
Is Beta Drugs financially healthy?
Beta Drugs has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Beta Drugs?
Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Beta Drugs?
Promoters hold a minority stake - exact percentages are in the full report. 14 active director(s) are on record.
Does Beta Drugs have loans or charges against its assets?
18 open charge(s) are registered against its assets, and 29 earlier charge(s) stand satisfied.
Is Beta Drugs up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).
Is it risky to lend to Beta Drugs?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
